Which is the best predictor of hepatitis activity in HBeAg-negative patients: Alanine transaminase (ALT), HBV DNA, Pre-Core/Core promoter mutation or viral genotypes?

2001 ◽  
Vol 120 (5) ◽  
pp. A554-A555 ◽  
Author(s):  
Joseph J.Y. Sung ◽  
Henry L.Y. Chan ◽  
May L. Wong ◽  
Chi-Hang Tse ◽  
John S.I. Tam ◽  
...  
2000 ◽  
Vol 118 (4) ◽  
pp. A935
Author(s):  
Ryo Fukuda ◽  
Mohammad Ak Rumi ◽  
Sachiko Hamamoto ◽  
Norihisa Ishimura ◽  
Shunji Ishihara ◽  
...  

2009 ◽  
Vol 16 (4) ◽  
pp. 259-264 ◽  
Author(s):  
M. Veazjalali ◽  
H. Norder ◽  
L. Magnius ◽  
S. M. Jazayeri ◽  
S. M. Alavian ◽  
...  

Blood ◽  
2014 ◽  
Vol 124 (20) ◽  
pp. 3151-3154 ◽  
Author(s):  
Joana R. Costa ◽  
Valentina S. Caputo ◽  
Kalliopi Makarona ◽  
D. Mark Layton ◽  
Irene A. G. Roberts ◽  
...  

Key Points B cells but not red cells are GPI deficient in PIGM-associated IGD, caused by a core promoter mutation that abrogates Sp1 binding. In red but not B cells, PIGM transcription is independent of Sp1 binding to the core promoter, hence GPI expression in red cells is near normal.


BMC Cancer ◽  
2022 ◽  
Vol 22 (1) ◽  
Author(s):  
Teng Huang ◽  
Jiaheng Li ◽  
San Ming Wang

Abstract Background Bladder cancer is one of the most mortal cancers. Bladder cancer has distinct gene expression signature, highlighting altered gene expression plays important roles in bladder cancer etiology. However, the mechanism for how the regulatory disorder causes the altered expression in bladder cancer remains elusive. Core promoter controls transcriptional initiation. We hypothesized that mutation in core promoter abnormality could cause abnormal transcriptional initiation thereby the altered gene expression in bladder cancer. Methods In this study, we performed a genome-wide characterization of core promoter mutation in 77 Spanish bladder cancer cases. Results We identified 69 recurrent somatic mutations in 61 core promoters of 62 genes and 28 recurrent germline mutations in 20 core promoters of 21 genes, including TERT, the only gene known with core promoter mutation in bladder cancer, and many oncogenes and tumor suppressors. From the RNA-seq data from bladder cancer, we observed  altered expression of the core promoter-mutated genes. We further validated the effects of core promoter mutation on gene expression by using luciferase reporter gene assay. We also identified potential drugs targeting the core promoter-mutated genes. Conclusions Data from our study highlights that core promoter mutation contributes to bladder cancer development through altering gene expression.


Sign in / Sign up

Export Citation Format

Share Document